Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.

Leandro Blas Masaki ShiotaTakashi MatsumotoYoshifumi HoriMotonobu NakamuraNarihito SekiKentaro KuroiwaAkira YokomizoFutoshi MorokumaKeijiro KiyoshimaMasatoshi Eto

Published in: International journal of urology : official journal of the Japanese Urological Association (2023)

This study stresses the importance of BMA use in patients with CRPC and bone metastases in Ra-223 treatment.

Keyphrases

combination therapy
systemic lupus erythematosus
soft tissue
replacement therapy
postmenopausal women